Thromboembolic Complications in Myelomatosis

Catovsky, Daniel; Ikoku, N. B.; Pitney, W. R.; Galton, D. J.

doi:10.1136/bmj.3.5720.438

Cited by 54 publications

(34 citation statements)

References 16 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 During the past decade, the introduction of the oral immunomodulatory drugs (IMiDs) thalidomide and lenalidomide has improved the clinical outcome of patients diagnosed with MM. [2][3] However, a high rate of thromboembolic complications has been observed when using these agents, especially in combination with chemotherapy and high-dose corticosteroids, 2,4-6 which has led to increased clinical awareness of VTE and research focus on the topic.…”

Section: Introductionmentioning

confidence: 99%

Thrombosis in Multiple Myeloma

Kristinsson

2010

Hematology

View full text Add to dashboard Cite

Patients with multiple myeloma (MM) are at an increased risk of venous and arterial thrombosis. The pathogenesis remains unclear, but probably involves several factors such as activation of procoagulant factors, acquired activated protein C resistance, and inflammation. In addition to general risk factors for venous thromboembolism, such as older age, immobility, surgery, and inherited thrombophilia, there are some MM-specific and treatment-related factors that contribute to the increased risk. The risk for venous thromboembolism is high when patients are treated with thalidomide or lenalidomide in combination with dexamethasone or multi-agent chemotherapy. Thromboprophylaxis should be given in these settings. Which agent is the most appropriate is a matter of debate, but aspirin, low-molecular-weight heparin, and warfarin all seem to be effective. This review discusses risk factors for thromboembolism in MM and general, disease-specific and treatment-related mechanisms for thrombosis. Recommendations for thromboprophylaxis are described and treatment choices for venous thrombosis in MM patients are reviewed.

show abstract

Section: Introductionmentioning

confidence: 99%

Thrombosis in Multiple Myeloma

Kristinsson

2010

Hematology

View full text Add to dashboard Cite

show abstract

“…Possible explanation of priapism in MM are (1) hyperviscosity related to paraproteinemia (2) Spontaneous platelet aggregation (3) or venous thrombosis secondary to drug effect eg. thalidomide (4) High fibrinogen and VIII levels (5) associated amyloid deposits [1,2]. In our case, hyperviscosity and spontaneous platelet aggregation might have played some role in causing priapism.…”

mentioning

confidence: 73%

“…CML). MM is a very unusual and rare cause of priapism [1][2][3]. On PubMed search, we found that only three cases of ''Priapism and Multiple myeloma'' have been reported so far till date.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Priapism as the Presenting Manifestation of Multiple Myeloma

Sahu

Mishra

Dhibar

et al. 2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

“…6 A hypercoagulable state in MM was recognized in the early 1970s, and MM was described as an independent risk factor for VTEs. 7,8 Before the introduction of IMiD therapy, ≈10% of patients with MM treated with chemotherapy experienced VTE complications, and the median time from diagnosis to the development of VTEs was 8.5 months. 9 VTEs have increasingly been observed in patients with MM treated with IMiDs, especially when used in combination with highdose dexamethasone or chemotherapy.…”

Section: Thrombosis and MMmentioning

confidence: 99%